Braidwell’s BioMarin Pharmaceuticals BMRN Stock Holding History

Braidwell’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-497,020	Closed	-$28.1M	–	88
2026 Q1	$28.1M	Sell	497,020 -104,500	-17%	-$6.09M	0.94%	41
2025 Q4	$35.7M	Buy	601,520 +73,520	+14%	+$4M	1.14%	34
2025 Q3	$28.6M	Buy	+528,000	New	+$30.2M	0.85%	35
2024 Q2	–	Sell	-218,896	Closed	-$19.1M	–	79
2024 Q1	$19.1M	Buy	+218,896	New	+$19.6M	0.62%	52

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Braidwell's BMRN Position: Q2 2026 in Review

Braidwell sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 497,020 shares — an estimated $28.1M sold.

Braidwell first reported a position in BMRN in Q1 2024 and held it in 4 quarters. The position peaked at $35.7M in Q4 2025. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Braidwell reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Braidwell sold 497,020 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $28.1M.
Braidwell first reported a position in BioMarin Pharmaceuticals in Q1 2024 and held it in 4 quarters.
Braidwell's BioMarin Pharmaceuticals position peaked at $35.7M in Q4 2025.
564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Braidwell's 13F filing for Q2 2026, filed 14 Aug 2026.